We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cannabidiol for Reducing Drinking in Alcohol Use Disorder (CARAMEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05159830
Recruitment Status : Not yet recruiting
First Posted : December 16, 2021
Last Update Posted : August 12, 2022
Sponsor:
Information provided by (Responsible Party):
Hôpital le Vinatier

Brief Summary:
The non-psychotomimetic cannabis compound cannabidiol (CBD) has been found effective for reducing alcohol drinking in mice. Moreover, other experimental studies have found that CBD reduced alcohol-induced steatosis in the liver, and reduced alcohol-related injury in the brain. Despite these promising results from animal data, no human study has been conducted yet in alcohol use disorder (AUD).

Condition or disease Intervention/treatment Phase
Alcohol Use Disorder Drug: Cannabidiol Cap/Tab Drug: Placebo Cap/Tab Phase 2

Detailed Description:

CBD has several potential therapeutic prospects in AUD. Preclinical studies now support the potential of CBD for drinking reduction in AUD subjects. Moreover, other experimental studies have found that CBD reverse the alcohol-induced steatosis process in the liver. These two experimental effects need a translational confirmation in humans through an explanatory phase 2 study. In addition, CBD could also exert neuroprotective effects that reduce the deleterious effects of alcohol on the brain. In both the liver and the brain, the idiosyncratic anti-inflammatory effects of CBD could thus strengthen the overall harm reduction allowed by drinking reduction in AUD ± ALD patients.

CBD deserves an exploratory study assessing whether the different therapeutic prospects in AUD are warranted. Moreover, because CBD is extracted from cannabis, and even if it is a CB1 antagonist with no psychotomimetic effects and no reported potential for abuse, the first pieces of evidence in AUD should confirm that CBD is safe in AUD subjects.

The CARAMEL study is a phase-2 clinical trial on 76 subjects, which aims to investigate the efficacy of CBD on reducing alcohol drinking, as well as the potential of CBD for restraining alcohol-induced brain and liver injuries, and confirm the good safety profile of CBD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: CARAMEL is a phase-2, national, multi-site, interventional (category 1), double-blind, randomized, placebo-controlled trial, conducted in 76 subjects.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

PANAXIA Pharmaceutical Industries Ltd will produce tablets of Cannabidiol and Placebo of similar galenic form. They will be responsible for the pharmaceutical analyses of the product.

Eurofins-LC2 will import the tablets after authorization from the ANSM, and will relabeled individual vials for each participant, and regular dispatching into the hospital pharmacy.

Local hospital pharmacies will be in charge to deliver treatment individual vials to the investigators for dispensing.

Primary Purpose: Treatment
Official Title: Cannabidiol for Reducing Drinking in Alcohol Use Disorder and Modifying the Effects of Alcohol on the Brain and the Liver: a Phase 2 Clinical Trial.-The CARAMEL Study
Estimated Study Start Date : October 3, 2022
Estimated Primary Completion Date : September 30, 2024
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Alcohol
Drug Information available for: Cannabidiol

Arm Intervention/treatment
Experimental: Cannabidiol (CBD)
CBD Group from 20mg x 2/day up to 600mg/day
Drug: Cannabidiol Cap/Tab
The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Sublingual tablet contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed tablet.

Placebo Comparator: PLACEBO (PCB)
PCB Group from 20mg x 2/day up to 600mg/day
Drug: Placebo Cap/Tab
Placebo of similar cannabidiol galenic form




Primary Outcome Measures :
  1. the total consumption of alcohol (in standard-drinks, sd) in the 28 last days (week 8 to week 12) of the study, using the Alcohol Timeline Followback (A-TLFB) daily self-report of alcohol drinking [ Time Frame: Five months ]
    The difference between the total alcohol consumption during 28 days preceding the study, and the 28 last days of the study, will be compared between the two groups.


Secondary Outcome Measures :
  1. Difference (i.e., inclusion minus end of study) in alcohol craving scores using the Obsessive Compulsive Drinking Scale (OCDS). [ Time Frame: Five months ]
    Inclusion minus end of study using the OCDS. The Obsessive Compulsive Drinking Scale (OCDS) is a 14-item questionnaire that measures an individual's alcohol use and his/her attempts to control his/her drinking. Each item is scored on a scale from 0 to 4.Obsessive subscale is the summation of items 1-6.Compulsive subscale is the summation of items 7-14.

  2. Difference in alcohol use disorder scores using the Alcohol Use Disorders Identification Test scale (AUDIT-C). [ Time Frame: Five months ]

    inclusion minus end of study The Alcohol Use Disorders Identification Test (AUDIT-C) is an alcohol screen that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence).

    Probable misuse: score > 4 for men and > 3 for women. Probable dependence: score > 10 regardless of sex.


  3. Difference in anxiety and depression Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Five months ]
    Inclusion minus end of study Each answer corresponds to a number. By adding these numbers, we obtain a total score per column (anxiety and depression). If the score of a column is greater than or equal to 11, it means that the subject suffers from anxiety or depression

  4. Difference in Controlled Attenuation Parameter (CAP) scores [ Time Frame: Five months ]
    Inclusion minus end of study Using ultra-sound electrography which measures liver steatosis using transient ultra-sound elastography, between V0 and V4

  5. Change in steatosis scores between V0 and V4, using Proton Density Fat Fraction (PDFF) estimated on the structural liver based on Chemical Shift Encoding-MRI (CSE-MRI) and MR Spectroscopy (MRS). [ Time Frame: Five months ]
    Inclusion minus end of study

  6. Between-group comparison of recovery of grey matter integrity in corticostriatal-limbic circuits, between V0 and V4, using MRI Voxel Based Morphometry (VBM) and cortical thickness measures. [ Time Frame: Five months ]
    Inclusion minus end of study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Being aged 18 - 65 years
  • Being fluent in French
  • Having read the information procedure and signed the informed consent sheet.
  • Being affiliated with health insurance.
  • DSM-5 criteria for AUD (all stages) (American Psychiatric Association, 2013)
  • Average drinking level of at least 12 standard-drinks (120g of ethanol) per day over the month prior to inclusion (i.e., a total alcohol consumption of 336 standard-drinks during the 28-day assessment period prior to inclusion), using the A-TLFB.

Exclusion Criteria:

  • At least one day of abstinence (no alcohol drinking) during the month prior to inclusion
  • Criteria for liver cirrhosis (Child-Pugh B or C)
  • DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder, using the MINI 7.0.2.
  • Current suicidality, using the MNI 7.0.2
  • Lifelong history of suicide attempts
  • Lifelong history or current DSM-5 criteria for substance use disorder (other than alcohol or nicotine) using the MINI 7.0.2.
  • Any detected use of cannabis or any other cannabinoid within 60 days prior to screen
  • Patients with transaminase elevations greater than 3 times upper the limit of normal and bilirubin greater than 2 times upper the limit of normal.
  • Impaired medical condition (investigator's decision)
  • Pregnancy, lactation, or insufficient contraceptive measure (precautionary measure) (See 5.2 for acceptable birth control methods)
  • Patients with cancer, HIV, pulmonary arterial hypertension, epilepsy and with rifampicin, St. John's wort, Mammalian target of rapamycin (mTOR), calcineurin inhibitors or triazole antifungal agents like posaconazole, fluconazole… .
  • History of vascular accident and/or cardiac arrhythmias and/or myocardial infarction
  • Patients receiving acamprosate, naltrexone, disulfiram, nalmefene, topiramate, baclofen for AUD within 30 days prior to screening.
  • MRI contraindication: pacemaker, insulin pump, heart metal valve, cochlear implant…
  • Known hypersensitivity to the active principle (cannabidiol) or excipients (sucralose, menthol, mannitol).
  • Person under tutorship or curatorship.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05159830


Contacts
Layout table for location contacts
Contact: Mathieu CHAPPUY, PhD 00 33 4 37 91 50 75 mathieu.chappuy@chu-lyon.fr
Contact: Véronique VIAL 00 33 4 37 91 55 31 veronqiue.vial@ch-le-vinatier.fr

Locations
Layout table for location information
France
Centre Hospitalier Le Vinatier
Bron, Auvergne Rhone Alpes, France, 69678 cedex
Sponsors and Collaborators
Hôpital le Vinatier
Investigators
Layout table for investigator information
Principal Investigator: Benjamin ROLLAND, MD, PhD Centre hospitalier le Vinatier
Layout table for additonal information
Responsible Party: Hôpital le Vinatier
ClinicalTrials.gov Identifier: NCT05159830    
Other Study ID Numbers: 2019-004740-30
First Posted: December 16, 2021    Key Record Dates
Last Update Posted: August 12, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcoholism
Alcohol Drinking
Drinking Behavior
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cannabidiol
Anticonvulsants